Efficacy of Curosurfact and Colistin for the treatment of neonatal respiratory distress syndrome(NRDS)and the influence on serum levels of TGF-β1 and BMP-7 in infants
Objective To explore the efficacy of Curosurfact and Colistin in the treatment of neonatal respiratory distress syn-drome(NRDS)and their impact on the levels of transforming growth factor-beta 1(TGF-β1)and bone morphogenetic pro-tein-7(BMP-7)in infants,to provide evidence for the treatment of NRDS in infants.Methods A total of 120 infants with NRDS admitted to the Department of Neonatology of our hospital,from October 2019 to November 2023,were selected as the participants for the study.They were assigned to the Curosurfact group and the Colistin group by block randomization,with 60 cases in each group.Both groups of infants were treated with minimally invasive percutaneous intratracheal instilla-tion of lung surfactant(LISA),with the Curosurfact group receiving Curosurfact and the Colistin group receiving Colistin.The therapeutic efficacy and adverse reactions and complications during the treatment of the two groups were compared.Meanwhile,the levels of serum cytokines(TGF-β1 and BMP-7)and inflammatory factors[procalcitonin(PCT)and C-reac-tive protein(CRP)]before and 24 hours after treatment in both groups were compared,as well as the neonatal behavioral neuro-assessment(NBNA)scores after treatment in both groups.Results No statistically significant differences were ob-served in the medication time,oxygen therapy days,and length of hospital stay between the two groups of infants(P＞0.05).The hospitalization costs of the Colistin group were significantly lower than those of the Curosurfact group(P＜0.05).No statistically significant difference was found in the incidence of adverse reactions and complications during treat-ment between the two groups(P＞0.05).Before treatment,no statistically significant difference was noted in the levels of serum TGF-β1 and BMP-7 between the two groups(P＞0.05).After treatment,the levels of serum TGF-β1 and BMP-7 in both groups were significantly lower than before treatment(P＜0.05),but there were no statistically significant differences between the groups(P＞0.05).Before treatment,there was no statistically significant difference in the levels of serum PCT and CRP between the two groups(P＞0.05).The levels of serum PCT and CRP in both groups were significantly declined after treatment(P＜0.05),but there were no statistically significant differences between the groups(P＞0.05).One week after treatment,there were no statistically significant differences in the Neonatal Behavioral Neurological Assessment(NBNA)scale scores of neonatal behavior,passive muscle tone,active muscle tone,primitive reflexes,and general condition between the two groups(P＞0.05).Conclusion The efficacy and safety of Curosurfact and Colistin in treating infants with NRDS are comparable,both effectively improving the levels of TGF-β1,BMP-7,inflammatory factors,and neurobehavioral development in infants.The most appropriate treatment plan can be adopted following the specific situation and needs of the infant.
万方数据
维普
